Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective

Monika Abramiuk; Ilona Skrabalak; Malgorzata Satora; Marta Ostrowska-Leśko; Maja Joanna Czech; Julia Majchrzak; Marcin Bobiński

doi:10.12659/MSM.949526

28 August 2025 : Review article

Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective

Monika Abramiuk

^{AEFG 1*}, Ilona Skrabalak

^{EF 2}, Malgorzata Satora

^{AEF 3}, Marta Ostrowska-Leśko

^{AEFG 2}, Maja Joanna Czech^{EF 4}, Julia Majchrzak^{EF 4}, Marcin Bobiński

^{AFG 2}

DOI: 10.12659/MSM.949526

Med Sci Monit 2025; 31:e949526

Authors information Article notes Copyright and License information

Introduction Characteristics of Ovarian Cancer The Idea of Tailored Therapy Mechanisms of Action of Currently Used Agents Clinical Utilization of Targeted Treatments Upcoming Advances Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 The most relevant clinical trials using Immune Checkpoint Inhibitors in Platinum-Resistant EOC.

Intervention (drug)	Target	Cohorts	Phase	Status	ClinicalTrials.gov ID	Publications
Pembrolizumab	PD-1	ROCPD-L1+n=26	I	Completed	NCT02054806	[–]¹²²
Pembrolizumab	PD-1	Cohort A:ROC1–3 prior treatment linesn=285Cohort B:ROCROC 4–6 prior treatment linesn=91	II	Completed	NCT02674061	[,]¹⁰³
Pembrolizumab + pegylated liposomal doxorubicin	PD-1	PR-ROC, fallopian tube or peritoneal cancern=26	II	Completed	NCT02865811	[]¹²⁵
Pembrolizumab + bevacizumab + cyclophosphamide	PD-1	PS-ROC, PR-ROCn=40	II	Completed	NCT02853318 []¹²⁶	[]¹²⁵
Pembrolizumab + niraparib	PD-1	PR-ROCn=62	I/II	Completed	NCT02657889 [,]¹²⁷	[,]¹¹⁵
Nivolumab;nivolumab + ipilimumab	PD-1, CTLA-4	PS-ROC, PR-ROCn=100	II	Active, not recruiting	NCT02498600 []¹²⁹	[]¹¹⁷
Nivolumab + bevacizumab;nivolumab + bevacizumab + rucaparib	PD-1	PS-EOC, PR-EOCn=38	II	Active, not recruiting	NCT02873962 []¹³⁰	[]¹¹⁸
Avelumab vs avelumab + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin	PD-L1	PR-ROCn=566	III	Completed	NCT02580058 []¹³¹	[]¹¹⁹
Avelumab + placebo vs entinostat + avelumab	PD-L1	PR-ROCn=126	I/II	Completed	NCT02915523	–
Durvalumab + pegylated liposomal doxorubicin	PD-L1	PR-ROCn=40	I/II	Completed	NCT02431559 []¹³¹	[]¹²⁰
Durvalumab + olaparib	PD-L1	PR-ROCn=35	I/II	Recruiting	NCT02484404 []¹³²	[]¹²¹
Tremelimumab vs tremelimumab + olaparib	CTLA-4	PR-ROCn=24	I	Terminated	NCT02485990	–
Avelumab	PD-L1	PR-ROCn=125	I	Completed	NCT01772004	[]¹³³
Bevacizumab + olaparib + durvalumab	VEGFPARPPD-L1	PS-ROCn=74	II	Unknown	NCT04015739	[]¹³⁴
Nivolumab vs nivolumab + ipilimumab	PD1, CTLA-4	Extra renal OCCCn=44	II	Active, not recruiting	NCT03355976	[]¹³⁵
Dostarlimab + niraparib	PD-1, PARP	PR-OCn=41	II	Completed	NCT03955471	[]¹³⁶
Dostarlimab + niraparib	PD-1, PARP	PR-ROCN=427	III	Unknown	NCT04679064	[]¹³⁷
Atezolizumab + niraparib	PD-L1, PARP	Recurrent EOCn=417	III	Completed	NCT03598270	[]¹³⁸
Atezolizumab + guadecitabine + CDX-1401 (vaccine)	PD-L1 + epigenetic modulator + NY-ESO-1 antigen	Recurrent EOCn=12	I/II	Completed	NCT03206047	–

Back to the Article

Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective

Your Privacy